SynthesisFrontiers in oncology2026
Prognostic significance of ypN status after neoadjuvant chemoimmunotherapy in resectable NSCLC: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemoimmunotherapy has become an important treatment strategy for resectable non-small cell lung cancer (NSCLC), yet postoperative relapse remains common. Although pathological response is increasingly used for prognostication, the prognostic value of post-treatment nodal status remains unclear. We therefore conducted a systematic review and meta-analysis to evaluate the association between ypN status and survival outcomes after neoadjuvant chemoimmunotherapy in resectable NSCLC. Methods: In accordance with PRISMA 2020 guidelines, PubMed, Web of Science, Scopus, Embase, and the Cochrane Library were searched from inception to February 26, 2026. Studies reporting survival outcomes stratified by pathological nodal response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy were included. Overall survival (OS) was prespecified as the primary outcome. Disease-free survival (DFS) was considered a secondary outcome, while recurrence-free survival (RFS) was summarized descriptively when quantitative pooling was not feasible. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using fixed- or random-effects models according to heterogeneity. Results: Two studies were included in the primary meta-analysis of OS. Across prespecified clinically comparable but non-identical nodal-response contrasts, unfavorable post-treatment nodal status was associated with significantly poorer OS (pooled HR 4.75, 95% CI 2.38 - 9.47; P < 0.00001; I² = 0%). A similar association was observed for DFS (pooled HR 3.54, 95% CI 1.71-7.33; P = 0.0007; I² = 0%). Sensitivity analyses showed consistent results. For RFS, only one study provided extractable data, suggesting that combined major pathological response (MPR)-ypN classification may further stratify prognosis, with the non-MPR ypN+ group showing the poorest outcome. Conclusions: Across prespecified clinically comparable but non-identical nodal-response contrasts, unfavorable post-treatment nodal status was associated with poorer survival outcomes in resectable NSCLC. Because the pooled OS and DFS analyses each included only two retrospective studies, these findings should be interpreted cautiously pending prospective validation with standardized pathological classifications and uniform survival endpoints. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420261353461.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.